drug
Ella
Marketedupdated 5mo agoby HRA Pharma LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(0)
nothing on the calendar yet
Trials studying Ella
- phase2A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
- phase2Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
- N/APivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
- N/AELEVATE High-Risk PCI Pivotal Study
- N/ABTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women
- —Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support
- phase1Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma
- N/ASIRONA 2 Trial Heart Failure NYHA Class III
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 8, 2028
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Jun 12, 2030method-of-use (U-1389)US 84263923.7y
- Jun 12, 2030method-of-use (U-1657)US 89626033.7y
- Jun 2, 2030formulationUS 85127453.7y
- Apr 13, 2030method-of-use (U-2510)US 101596813.5y
- Apr 13, 2030method-of-use (U-2958)US 107728973.5y
- Apr 13, 2030method-of-use (U-1821)US 92832333.5y
- Feb 20, 2029formulationUS 87353802.4y
- Dec 8, 2028formulationUS 98445102.2y
News(1)
- Opinion: Telehealth abortion with mifepristone continues, with backup plans still in placeRestricting telehealth prescribing of mifepristone wouldn't spell the end of telehealth medication abortion, writes OB-GYN Christine Henneberg.stat · 4mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that